SCHEMBL23367197

SCHEMBL23367197

CCOC(=O)/C(C=O)=N/Nc1ccc(Br)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KYAT1 Q16773 5/20 0.58
GAA P10253 7/20 0.53
ATM Q13315 2/20 0.53
KMT2A Q03164 5/20 0.48
MEN1 O00255 4/20 0.48
MAPT P10636 4/20 0.48
LMNA P02545 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
S1PR4 O95977 1/20 0.48
S1PR1 P21453 1/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 6/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
NPC1 O15118 1/20 0.42
DHODH Q02127 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23354735 0.89 KYAT1 (0.56) KYAT1GAAATMKMT2AMEN1
SCHEMBL23367209 0.89 KYAT1 (0.56) KYAT1GAAATMKMT2AMEN1
SCHEMBL23354736 0.89 KYAT1 (0.56) KYAT1GAAATMKMT2AMEN1
SCHEMBL23367424 0.86 KYAT1 (0.56) KYAT1GAAATMKMT2AMEN1
SCHEMBL23354697 0.86 MAPT (0.55) KYAT1GAAATMKMT2AMEN1
SCHEMBL23354800 0.86 MEN1 (0.60) KYAT1GAAATMKMT2AMEN1
SCHEMBL23367177 0.86 MAPT (0.55) KYAT1GAAATMKMT2AMEN1
SCHEMBL23354802 0.86 MEN1 (0.60) KYAT1GAAATMKMT2AMEN1
SCHEMBL23354676 0.86 GAA (0.59) KYAT1GAAATMKMT2AMEN1
SCHEMBL23367248 0.86 GAA (0.59) KYAT1GAAATMKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058446-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094434-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822265-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer AG (DE) 2021-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027985-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAMTS1 KYAT1 2133/4885GAA 1454/4885ATM 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.